169 related articles for article (PubMed ID: 37400692)
1. Insulin use and gout risk among patients with type 2 diabetes mellitus: a real-world cohort study in Shanghai, China.
Qi J; He P; Yao H; Sun W; Lu P; Qi X; Zhang Z; Jing R; Cui B; Liu D; Ning G
Clin Rheumatol; 2023 Nov; 42(11):3067-3073. PubMed ID: 37400692
[TBL] [Abstract][Full Text] [Related]
2. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
[TBL] [Abstract][Full Text] [Related]
4. Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study.
Wijnands JMA; van Durme CMPG; Driessen JHM; Boonen A; Klop C; Leufkens B; Cooper C; Stehouwer CDA; de Vries F
Medicine (Baltimore); 2015 Aug; 94(32):e1358. PubMed ID: 26266391
[TBL] [Abstract][Full Text] [Related]
5. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.
Chang HW; Lin YW; Lin MH; Lan YC; Wang RY
PLoS One; 2019; 14(1):e0210085. PubMed ID: 30615649
[TBL] [Abstract][Full Text] [Related]
6. Decreased incidence of gout in diabetic patients using pioglitazone.
Niu SW; Chang KT; Lin HY; Kuo IC; Chang YH; Chen YH; Hung CC; Chiu YW; Hwang SJ
Rheumatology (Oxford); 2018 Jan; 57(1):92-99. PubMed ID: 29040733
[TBL] [Abstract][Full Text] [Related]
7. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study.
Fang YJ; Chung YL; Lin CL; Lim YP
Biomed Res Int; 2020; 2020():6358954. PubMed ID: 32775432
[TBL] [Abstract][Full Text] [Related]
8. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
Zhou J; Liu X; Chou OH; Li L; Lee S; Wong WT; Zhang Q; Chang C; Liu T; Tse G; Jing F; Cheung BMY
Rheumatology (Oxford); 2023 Apr; 62(4):1501-1510. PubMed ID: 36066415
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Fralick M; Chen SK; Patorno E; Kim SC
Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
[TBL] [Abstract][Full Text] [Related]
10. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study.
Chu CC; Chen YC; Lin MH; Wu WT; Liu FC; Chen HC; Chou YC; Sun CA
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329085
[TBL] [Abstract][Full Text] [Related]
11. Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.
Chuang JP; Lee JC; Leu TH; Hidajah AC; Chang YH; Li CY
BMJ Open; 2019 Oct; 9(10):e028892. PubMed ID: 31601586
[TBL] [Abstract][Full Text] [Related]
12. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
Kuo S; Yang CT; Wu JS; Ou HT
Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
Tseng CH
BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
[TBL] [Abstract][Full Text] [Related]
14. Association Between Gout and Incident Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Tung YC; Lee SS; Tsai WC; Lin GT; Chang HW; Tu HP
Am J Med; 2016 Nov; 129(11):1219.e17-1219.e25. PubMed ID: 27448491
[TBL] [Abstract][Full Text] [Related]
15. Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls.
Ferguson LD; Molenberghs G; Verbeke G; Rahimi K; Rao S; McInnes IB; McMurray JJV; Sattar N; Conrad N
Lancet Rheumatol; 2024 Mar; 6(3):e156-e167. PubMed ID: 38383089
[TBL] [Abstract][Full Text] [Related]
16. Contributing Factors of Diabetes Mellitus among Patients with Gout (Results of the Long-Term Prospective Study).
Zheliabina OV; Eliseev MS; Glukhova SI; Nasonov EL
Dokl Biochem Biophys; 2023 Aug; 511(1):195-202. PubMed ID: 37833606
[TBL] [Abstract][Full Text] [Related]
17. Urate-lowering Therapy and Chronic Kidney Disease Development in Patients with Gout.
Yen FS; Wei JC; Chang CL; Yang CC; Hsu CC; Hwu CM
Int J Med Sci; 2021; 18(12):2599-2606. PubMed ID: 34104091
[No Abstract] [Full Text] [Related]
18. Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study.
Kollhorst B; Behr S; Enders D; Dippel FW; Theobald K; Garbe E
Diabetes Obes Metab; 2015 Dec; 17(12):1158-65. PubMed ID: 26279482
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study.
Kok VC; Horng JT; Chang WS; Hong YF; Chang TH
PLoS One; 2014; 9(6):e99102. PubMed ID: 24897240
[TBL] [Abstract][Full Text] [Related]
20. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
Tseng CH
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
